{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:34:23Z","timestamp":1793090063853,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105548","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T14:59:17Z","timestamp":1786805957000},"page":"105548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Lurbinectedin in the therapeutic landscape of SCLC: Key clinical evidence and evolving role in the era of emerging therapies"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9400-4676","authenticated-orcid":false,"given":"Andrea","family":"Monte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Andrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Stumpo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giovanna","family":"Formelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Zappi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Scognamiglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Di Odoardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lamberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.critrevonc.2026.105548_bib1","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/imj.16348","article-title":"Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme","volume":"54","author":"Alexander","year":"2024","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.critrevonc.2026.105548_bib2","unstructured":"Agency for Therapeutic Products S. Swiss Public Assessment Report \u2013 Zepzelca, 2023. Available at: www.swissmedic.ch."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105548_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S2213-2600(22)00309-5","article-title":"Combination lurbinectedin and doxorubicin versus physician\u2019s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial","volume":"11","author":"Aix","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.critrevonc.2026.105548_bib4","unstructured":"Aix S.P., Navarro A., Eugenia M., Garcia O., Mezquita L., Majem M., et al. Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: Results of the 2SMALL phase 1\/2 study (NCT04253145). 2026."},{"key":"10.1016\/j.critrevonc.2026.105548_bib5","first-page":"12","article-title":"Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment","author":"Allavena","year":"2022","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105548_bib6","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2017.205","article-title":"Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models","volume":"117","author":"Belgiovine","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105548_bib7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12032-018-1194-4","article-title":"Patient performance status and cancer immunotherapy efficacy: a meta-analysis","volume":"35","author":"Bersanelli","year":"2018","journal-title":"Med. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105548_bib8","article-title":"A phase III study of lurbinectedin alone or in combination with irinotecan versus investigator\u2019s choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial)","volume":"41","author":"Besse","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105548_bib9","doi-asserted-by":"crossref","first-page":"8086","DOI":"10.1200\/JCO.2026.44.16_suppl.8086","article-title":"IMforte: Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of first-line maintenance treatment with lurbinectedin plus atezolizumab versus atezolizumab in extensive-stage small-cell lung cancer (ES-SCLC)","volume":"44","author":"Borghaei","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105548_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2026.2330","article-title":"Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320)","author":"Bozorgmehr","year":"2026","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105548_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.canlet.2014.01.005","article-title":"Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy?","volume":"346","author":"Bowden","year":"2014","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105548_bib12","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1158\/1535-7163.MCT-24-0050","article-title":"Unveiling the Mechanism of Lurbinectedin\u2019s Action and Its Potential in Combination Therapies in Small Cell Lung Cancer","volume":"24","author":"Calles","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105548_bib13","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jtho.2025.02.005","article-title":"Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I\/II LUPER Study","volume":"20","author":"Calles","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105548_bib14","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1158\/1078-0432.CCR-23-0471","article-title":"De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways","volume":"29","author":"Chakraborty","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105548_bib15","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312)","volume":"19","author":"Cheng","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105548_bib16","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105548_bib17","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1002\/cncr.34348","article-title":"Differential prognostic effect of systemic inflammation in patients with non\u2013small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 trial","volume":"128","author":"Cortellini","year":"2022","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105548_bib18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cllc.2023.09.001","article-title":"Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer","volume":"24","author":"Desai","year":"2023","journal-title":"Clin. Lung Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105548_bib19","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105548_bib20","doi-asserted-by":"crossref","first-page":"9248","DOI":"10.3390\/ijms21239248","article-title":"Role of Nucleotide Excision Repair in Cisplatin Resistance","volume":"21","author":"Duan","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105548_bib21","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1200\/JCO.2006.08.3998","article-title":"Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer","volume":"25","author":"Eckardt","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105548_bib22","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105548_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103968","article-title":"Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study","volume":"9","author":"Girard","year":"2024","journal-title":"ESMO Open."},{"issue":"17_","key":"10.1016\/j.critrevonc.2026.105548_bib24","first-page":"LBA8005","article-title":"Concurrent thoracic radiotherapy (TRT), platinum-etoposide chemotherapy, and durvalumab immunotherapy in extensive-stage small-cell lung cancer (ES-SCLC): a phase III trial","volume":"44","author":"Gr\u00f8nberg","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105548_bib25","unstructured":"Jazz Pharmaceuticals provides update on Zepzelca\u00ae (lurbinectedin) phase 3 LAGOON trial in second-line small cell lung cancer. News release. June 12, 2026. Available at: https:\/\/investor.jazzpharma.com\/news-releases\/news-release-details\/jazz-pharmaceuticals-provides-update-zepzelcar-lurbinectedin\/."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105548_bib26","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2025.0560","article-title":"Small Cell Lung Cancer","volume":"333","author":"Kim","year":"2025","journal-title":"JAMA"},{"issue":"35","key":"10.1016\/j.critrevonc.2026.105548_bib27","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1200\/JCO.23.01435","article-title":"Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline","volume":"41","author":"Khurshid","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105548_bib28","first-page":"205","article-title":"Lurbinectedin for extensive stage \u2212 small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes","author":"Krayim","year":"2025","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105548_bib29","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.21037\/tlcr-21-437","article-title":"SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer","volume":"10","author":"Kundu","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105548_bib30","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1476-5381.2010.00945.x","article-title":"PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity","volume":"161","author":"Leal","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105548_bib31","article-title":"Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105548_bib32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105548_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0169-5002(00)00127-6","article-title":"A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis","volume":"30","author":"Mascaux","year":"2000","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105548_bib34","first-page":"12","article-title":"Lurbinectedin in small cell lung cancer","author":"Manzo","year":"2022","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105548_bib35","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/1759-7714.14382","article-title":"High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin","volume":"13","author":"Matsui","year":"2022","journal-title":"Thorac. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105548_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0169-5002(02)00072-7","article-title":"Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer\u2014what limits limited disease?","volume":"37","author":"Micke","year":"2002","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105548_bib37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"New. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105548_bib38","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105548_bib39","article-title":"Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC Trial","author":"Novello","year":"2026","journal-title":"J. Thorac. Oncol."},{"issue":"34","key":"10.1016\/j.critrevonc.2026.105548_bib40","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1200\/JCO.2006.06.5821","article-title":"Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer","volume":"24","author":"O\u2019Brien","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105548_bib41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/JTO.0b013e31819140fb","article-title":"Prognostic Factors for Survival in Extensive Stage Small Cell Lung Cancer (ED-SCLC): The Importance of Smoking History, Socioeconomic and Marital Statuses, and Ethnicity","volume":"4","author":"Ou","year":"2009","journal-title":"J. Thorac. Oncol."},{"issue":"10212","key":"10.1016\/j.critrevonc.2026.105548_bib42","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"10495","key":"10.1016\/j.critrevonc.2026.105548_bib43","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105548_bib44","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1200\/JCO.2026.44.16_suppl.8014","article-title":"Transcriptomic analyses of molecular subsets and correlations with clinical outcomes from the phase 3 IMforte study of lurbinectedin plus atezolizumab maintenance treatment in extensive-stage small-cell lung cancer (ES-SCLC)","volume":"44","author":"Paz-Ares","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2026.105548_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.8094","article-title":"Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in patients (Pts) with relapsed small cell lung cancer (SCLC): Results from a phase 2 expansion cohort","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.critrevonc.2026.105548_bib46","doi-asserted-by":"crossref","first-page":"107448","DOI":"10.1016\/j.lungcan.2023.107448","article-title":"Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval \u226530 days and without central nervous metastases","volume":"188","author":"Peters","year":"2024","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105548_bib47","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1158\/1078-0432.CCR-14-2958","article-title":"Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?","volume":"21","author":"Pietanza","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105548_bib48","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.1158\/0008-5472.CAN-16-0549","article-title":"Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming","volume":"76","author":"Rodriguez-Ruiz","year":"2016","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105548_bib49","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/ijc.28213","article-title":"Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis\u00ae (PM00104)","volume":"133","author":"Romano","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105548_bib50","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105548_bib51","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105548_bib52","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023"},{"key":"10.1016\/j.critrevonc.2026.105548_bib53","doi-asserted-by":"crossref","first-page":"S636","DOI":"10.1016\/j.annonc.2023.09.2189","article-title":"1050P Sensitization to immunotherapy through manipulation of tumor transcription by lurbinectedin","volume":"34","author":"Russo-Cabrera","year":"2023","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105548_bib54","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-16-0172","article-title":"Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells","volume":"15","author":"Santamar\u00eda Nu\u00f1ez","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105548_bib55","first-page":"226","article-title":"Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort","author":"Scattolin","year":"2025","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105548_bib56","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217313","article-title":"ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer","volume":"15","author":"Schultz","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105548_bib57","series-title":"Mol Cancer Ther","first-page":"OF1","article-title":"ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin","author":"Shields","year":"2026"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105548_bib58","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1158\/1078-0432.CCR-20-3901","article-title":"FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer","volume":"27","author":"Singh","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105548_bib59","doi-asserted-by":"crossref","first-page":"9537","DOI":"10.1093\/nar\/gky764","article-title":"Base and nucleotide excision repair facilitate resolution of platinum drugs-induced transcription blockage","volume":"46","author":"Slyskova","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"9962","key":"10.1016\/j.critrevonc.2026.105548_bib60","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","article-title":"Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial","volume":"385","author":"Slotman","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105548_bib61","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2020.10.003","article-title":"Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment","volume":"150","author":"Subbiah","year":"2020","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105548_bib62","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00428-020-02840-6","article-title":"Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq","volume":"478","author":"Takashima","year":"2021","journal-title":"Virchows Arch."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105548_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151050","article-title":"Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary","volume":"11","author":"Takahashi","year":"2016","journal-title":"PLoS. One"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105548_bib64","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105548_bib65","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/JTO.0000000000000142","article-title":"Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes","volume":"9","author":"Varghese","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"35","key":"10.1016\/j.critrevonc.2026.105548_bib66","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2013.54.5392","article-title":"Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer","volume":"32","author":"von Pawel","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105548_bib67","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105548_bib68","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","article-title":"SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection","volume":"18","author":"Wang","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105548_bib69","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1656502","article-title":"Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity","volume":"8","author":"Xie","year":"2019","journal-title":"Oncoimmunology"},{"issue":"37","key":"10.1016\/j.critrevonc.2026.105548_bib70","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"109","author":"Zoppoli","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600435X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600435X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:45:41Z","timestamp":1793087141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282600435X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":70,"alternative-id":["S104084282600435X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105548","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lurbinectedin in the therapeutic landscape of SCLC: Key clinical evidence and evolving role in the era of emerging therapies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105548","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105548"}}